AlphAIAlphAI — Financial news for AI agents
stocktitan.netSEP 42 min read$GOSS

Biotech Gossamer Bio (NASDAQ: GOSS) markets $125M more in private securities

Gossamer Bio (GOSS) filed a Form D notice with the SEC, raising $125M through private securities offerings. The biotech firm, based in San Diego, did not disclose revenue. The offering includes options, warrants, and other rights to acquire securities. Leerink Partners LLC is involved as a broker-dealer.

Original reporting
stocktitan.net
Published Sep 4, 2026, 8:52 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 5, 2026, 2:42 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$GOSS
Bearish
high confidence
Mentioned
$GOSS
Relevance
8/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$GOSSBearishHigh
01

Why it matters

The filing provides the first public notice of the raise, likely leading to short‑term price pressure while funding R&D.

02

Market read

Primary corporate action for a micro‑cap biotech; relevant for traders monitoring dilution events.

03

What to watch

Potential strategic investors in the private placement could bring partnerships or validation not reflected in the filing.

Relevance 8/10Novelty 8/10Timing: immediate post‑filing

Background

Gossamer Bio filed a Form D on Aug 20, 2026, indicating a new private securities offering of $125M, with the first sale yet to occur.

Company-level read

Ticker impact

$GOSSBearishHigh confidence
Context

SEC Form D filing discloses $125M additional private securities offering, a new capital raise for Gossamer Bio.

Expected impact

Potential near‑term price dip of 3‑5% as market prices in dilution, with upside if funds accelerate clinical progress.

Evidence & confidence

Primary disclosure of a sizable private placement; market typically reacts negatively to dilution announcements.

Market effects

Sector

May signal increased financing activity in biotech sector, prompting investors to reassess other micro‑cap pipelines.

Regional

Limited to US biotech investors; no broader regional effect.

Global

Low global relevance beyond biotech niche.

Counterpoint

What could challenge this read

If the capital will fund a breakthrough trial, the dilution could be outweighed by future upside, making a short‑term dip a buying opportunity.

Key entities

  • Company
    Gossamer Bio, Inc.

    Biotech company issuing private securities.

Read at source← All news

Related articles

OCT 13
$GOSSMed

Chardan initiates Gossamer Bio stock with buy on PAH therapy potential

Chardan initiated coverage on Gossamer Bio (NASDAQ:GOSS) with a Buy rating and $160 price target, citing potential FDA approval of seralutinib for PAH therapy. The stock is near its 52-week low at $9.28. The company has a market cap of $56.76M and faces an NDA decision in Q4 2026. Chardan estimates $1.3B in 2035 revenue if approved. Gossamer recently submitted an NDA for seralutinib, supported by clinical trial data. Leerink and H.C. Wainwright also issued positive ratings.

investing.com2 min
SEP 23
$GOSSMedAI 8/10

Gossamer Bio (GOSS) Files NDA for Seralutinib Amidst Challenging

Gossamer Bio (GOSS) filed an NDA for seralutinib, its treatment for pulmonary arterial hypertension. The submission is based on clinical data from the PROSERA and TORREY studies, though the PROSERA trial did not meet its primary endpoint. GOSS trades at a P/S ratio of 0.62, below its historical median and industry averages, reflecting market skepticism. The company has a GF Score of 22/100, indicating significant financial and operational challenges.

gurufocus.com2 min
SEP 23
$GOSSHighAI 8/10

Gossamer Bio stock rises on FDA filing for PAH drug

Gossamer Bio (GOSS) shares rose 3.7% after-hours after submitting a New Drug Application for seralutinib, a treatment for pulmonary arterial hypertension, to the FDA. The submission is backed by Phase 3 and Phase 2 study data. The FDA will decide whether to accept the application for review later this year.

investing.com2 min
SEP 23
$GOSSMedAI 8/10

Gossamer Bio, Inc. announced that it submitted a New Drug Application to the U.S. Food and Drug Administration in September 2026 for seralutinib for the…

Gossamer Bio, Inc. (GOSS) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On September 23, 2026, Gossamer Bio, Inc. (the “Company”) announced that it submitted a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) in September 2026 for seralutinib for the treatment of pulmonary arterial hypertension (“P

SEC EDGAR 8-K2 min
AUG 27
$GOSSMedAI 8/10

Gossamer (GOSS) Announced Up to $250M of Financing, but Only $25M is Expected Upfront. Is the Runway Secure?

Gossamer Bio (GOSS) announced a private placement with up to $250M in gross proceeds, but only $25M is expected upfront. The remaining funds are contingent on regulatory milestones for seralutinib, a drug for pulmonary arterial hypertension. The company ended June with $57M in cash, expecting the initial $25M to improve near-term liquidity but not fully secure its runway.

insidermonkey.com3 min